The Global Biosimilar Monoclonal Antibodies Market was valued at US$ 1,516.9 Mn in 2016 and is projected to reach US$ 32,015.0 Mn in 2026 at a CAGR of 35.7% from 2017 to 2026. The Adalimumab drug class segment is estimated to account for the major revenue share of 29.1% by end of 2017, owing to its cost-effectiveness and capability to cure oncological diseases, Crohn’s colitis disease, and spondylitis.
The report offers in-depth insights, revenue details, and other vital information regarding the global biosimilar monoclonal antibodies market and the various trends, drivers, restraints, opportunities, and threats in the target market till 2026. The report also offers insightful and detailed information regarding the various key players operating in the global biosimilar monoclonal antibodies market, and their financials, apart from strategies, acquisitions & mergers, and market footprint.
